Summary
EudraCT Number: 2006-006436-22
Sponsor's Protocol Code Number: BAY a 1040 - BAY 68-9291/12313
National Competent Authority: Italy - Italian Medicines Agency 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2007-06-05
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006436-22/IT/

A. Protocol Information
A.1 Member State Concerned: Italy - Italian Medicines Agency
A.2 EudraCT number: 2006-006436-22
A.3 Full title of the trial: A multicenter Study Evaluating the Efficacy of Nifedipine GITS ﾖ Telmisartan Combination in Blood Pressure Control and Beyond: comparison of two strategies.
A.3.2 Name or abbreviated title of the trial where available: TALENT
A.4.1 Sponsor's protocol code number: BAY a 1040 - BAY 68-9291/12313
A.5.1 ISRCTN (International Standard Randomised Controlled Trial) number: ND
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: BAYER
B.1.3.4	Country: Italy
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: ADALAT CRONO
D.2.1.1.2 Name of the Marketing Authorisation holder: BAYER SpA
D.2.1.2 Country which granted the Marketing Authorisation: Italy
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Gastro-resistant tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: nifedipine GITS
D.3.9.1 CAS number: 21829-25-4
D.3.9.2 Current sponsor code: BAY a 1040
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 20 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: PRITOR
D.2.1.1.2 Name of the Marketing Authorisation holder: BAYER SpA
D.2.1.2 Country which granted the Marketing Authorisation: Italy
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: telmisartan
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 40 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Hypertension
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 6.1
E.1.2 Level: PT
E.1.2 Classification code: 10020772
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Evaluate the efficacy in blood pressure control when anti-hypertensive therapy is initiated with a combination of low dose Nifedipine GITS and Telmisartan  compared to a regimen starting with monotherapy before adding the other drug.
E.2.2 Secondary objectives of the trial: The effect of treatment on the metabolic and inflammation markers as indicators of cardiovascular risk will also be assessed.
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: - Hypertension (office systolic blood pressure > 135 mmHg),  untreated or poorly controlled but stable antihypertensive regimen for >= 4 weeks  - Presence of type 2 diabetes mellitus or target organ damage (echocardiographic or electrocardiographic left ventricular hypertrophy or microalbuminuria )  - Presence of a metabolic syndrome, i.e at least two of the following:  (a) impaired glucose tolerance (fasting plasma glucose 110 ﾖ 125 mg/dl)  (b) raised serum triglycerides (>= 150 mg/dl)  (c) low HDL cholesterol (males: < 40 mg/dl, females: < 50 mg/dl)  (d) waist circumference >102 cm in men and >88 cm in women  - Age: 18-75 years  - Negative pregnancy test in females  - Written informed consent
E.4 Principal exclusion criteria: - Ongoing treatment with the following drugs: ACE-inhibitors (e.g. captopril, benazepril, enalapril, lisinopril, fosinopril, ramipril, perindopril, quinapril, moexipril, and trandolapril), AT1-antagonists (e.g. losartan, candesartan, eprosartan, telmisartan) or calcium-antagonists (e.g. amlodipine, felodipine, isradipine, nifedipine, nimodipine) that  cannot be withdrawn.  - Concomitant treatment with other antihypertensive medication  that cannot be safely withdrawn at entry.  - Concomitant treatment with known cytochrome P450-3A4 inhibitors (e.g cimetidine, anti-HIV protease inhibitors e.g. ritonavir, azole anti-mycotics eg. Ketoconazole, digoxin, quinidine, tacrolimus) or inducers such as anti-epileptic drugs (eg. phenytoin, carbamazepine and phenobarbitone) or rifampicin  - Concomitant treatment with potassium sparing diuretics.  - Malignant, severe or labile essential hypertension, orthostatic hypotension  - Cardiovascular shock  - Evidence of secondary form of hypertension, including coarctation of the aorta, hyperaldosteronism, renal artery stenosis or pheochromocytoma  - Myocardial infarction or unstable angina within the previous 12 months  - Severe cardiac valve disease   - Severe rhythm or conduction disorder:  - bradycardia on physical examination at rest (HR < 50/min)  - tachycardia on physical examination at rest (HR > 100/min)  - frequent complex ventricular arrythmias  - atrial fibrillation  - intraventricular conduction disorders, Wolf Parkinson White syndrome  - sino-atrial, second degree or third degree A-V block  - baseline QTc > 450 msec  - Cerebrovascular ischaemic event (stroke, transient ischaemic attack) within the previous 12 months  - History of intra-cerebral haemorrhage or sub-arachnoid haemorrhage within the previous 12 months  - Type 1 diabetes mellitus  - Proteinuria (determined by uristix)   - BMI > 34  - Uncorrected hypokalemia or hyperkalemia, potassium outside the range 3.0 to 5.5 mmol/l  - Sodium depletion and/or hypovolemia   - Gastrointestinal disease resulting in the potential for malabsorption.  - Severe gastrointestinal tract narrowing   - Kock pouch (ileostomy after proctocolectomy)  - Cholestasis or biliary obstruction  - Liver disease or transaminase (AST, ALT) levels > 3 x the upper limit of normal range.  - Renal failure, creatinine >2.0 mg/dl  - Any malignant disease that has required treatment within the last five years.  - Dementia or psychosis.  - History of non-compliance, alcoholism or drug abuse.  - Treatment with any other investigational drug in the 30 days prior to entering the study.  - Pregnancy and lactation  - Known state of allergy, hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan  - Any surgical or medical condition which, at the discretion of the investigator, place the subject at higher risk from his/her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period.  - History of non compliance to medical regimens or subjects unwilling to comply with the study protocol.
E.5 End points
E.5.1 Primary end point(s): La valutazione dellﾒend-point sara' effettuata in cieco.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: Information not present in EudraCT
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): Yes
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: stessi farmaci in associazione
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 2
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 2

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): No
F.1.1.6 Adolescents (12-17 years): No
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 300
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 400
F.4.2.2 In the whole clinical trial: 400

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2007-08-29
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2007-05-25

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2009-11-06

